Volume 20, Number 7—July 2014
Genome Analysis of Mayaro Virus Imported to Germany from French Guiana
To the Editor: Mayaro virus (MAYV), a mosquito-borne New World alphavirus of the family Togaviridae, causes a febrile arthralgia syndrome resembling dengue and chikungunya fever. The virus is maintained in a natural cycle involving nonhuman primates and Haemagogus spp. mosquitoes in tropical rainforest areas of South America (1). After an incubation time of 7–12 days following an infectious mosquito bite, rash, fever, headache, and arthralgia develop in patients, followed by restoration to their original conditions after several weeks (1).
Outbreaks of Mayaro fever have been reported from the Amazon region (1,2). There are increasing reports of travel-related infections imported from South America to Europe and the United States (3–7). We describe an acute MAYV infection in a German traveler who returned from French Guiana. Full-length MAYV genome amplification was performed on virus obtained from a serum sample of the patient.
In August 2013, a 44-year-old woman (bookkeeper) came to an outpatient clinic with fever (temperature ≤38.7°C), chills, a mild headache, severe fatigue, highly painful swelling of small finger joints, and pain in both feet. Symptoms appeared 2 days before when she experienced aches in her wrists and left forefoot. Four days before, the patient had returned from a 2.5-week visit to French Guiana, where she traveled with her partner and caught butterflies. She had conducted these activities during her holidays for the past 5 years, mostly in spring or autumn. In July 2013 at the end of the rainy season, she had many mosquito bites, especially on her hands, despite use of repellents and bed nets.
Physical examination showed a body temperature of 38°C, throat enanthema, generalized macular exanthema, and slightly swollen and tender interphalangeal joints of the hands and feet. Her medical history was unremarkable, and her partner was asymptomatic. Laboratory tests showed reference values for hemoglobin concentration; platelet count; and levels of liver enzymes, creatinine, and anti-nuclear and anti–citrulline peptide antibodies. C-reactive protein level was increased (24.2 mg/L; reference value <5 mg/L), and serum lactate dehydrogenase level was slightly increased (4.4 μkat/L; reference value <4.12 μkat/L). Leukopenia (2.4 G/L; reference value 4.0–10.0 G/L) was present, which intensified the next day (2.0 g/L). The leukocyte count returned to a reference value 8 days after disease onset and the patient fully recovered.
Malaria, dengue fever, and rickettsiosis were excluded by using several tests. Blood cultures obtained on day 2 after disease onset remained sterile, and a viral infection was suspected. Follow-up investigation on day 16 of illness showed an increased IgG titer (80) against chikungunya virus (by indirect immunofluorescence assay; reference value <1:20) (6) but no IgM titer. Additional tests for alphaviruses were then performed on the same sample, and indirect immunofluorescence assay showed an IgM titer of 2,560 and an IgG titer of 10,240 (reference value <20) (6) against MAYV. Results of serologic tests were negative for Venezuelan equine encephalitis virus, Eastern equine encephalitis virus, and Oropouche virus. IgM (80) and IgG (160) titers for antibodies against Ross River virus were low.
An acute MAYV infection was strongly suspected and a stored serum sample from day 2 underwent generic reverse transcription PCR (RT-PCR) for alphaviruses with primers VIR2052F (5′-TGGCGCTATGATGAAATCTGGAATGTT-3′) and VIR2052R (5′-TACGATGTTGTCGTCGCCGATGAA-3′) (8) and quantitative MAYV real-time RT-PCR (in-house) with primers MayaroF (5′-CCTTCACACAGATCAGAC-3′), MayaroR (5′-GCCTGGAAGTACAAAGAA-3′), probe labeled with 6- carboxyfluorescein (FAM) and black hole quencher 1 (BHQ-1) MayaroP (5′-FAM-CATAGACATCCTGATAGACTGCCACC-BHQ1–3′) by using the AgPath-ID One-Step RT-PCR Kit (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions. The generic RT-PCR for alphaviruses showed a positive result, and direct sequencing of the amplicon showed a MAYV-specific sequence. The serum sample had an MAYV viral load of 1.24 × 107 copies/mL when in vitro–transcribed RNA from a reference plasmid was used as a quantification standard.
Attempts to isolate MAYV in cell culture were not successful. Therefore, the serum sample was used to obtain the complete MAYV genome sequence by using primers designed from multiple alignments of the MAYV genomes obtained from databases. (Primer sequences used are available on request.) The complete MAYV genome (strain BNI-1, KJ013266) was amplified from the serum sample, and phylogenetic analysis of a 2-kb genomic fragment showed that strain BNI-1 belonged to genotype D (9) and is closely related to strains circulating in Brazil (Figure, Appendix).
In 2 clinic-based syndromic surveillance studies in South America, 0.8%–3% of febrile episodes were caused by MAYV infection (2,10). In travelers, MAYV infections were acquired in tropical rainforest or wildlife conservation areas (7) and were sometimes associated with insect-hunting activities (5). Successful complete genome amplification of MAYV strain BNI-1 from a clinical sample might help identify regions in the MAYV genome that undergo rapid mutations caused by the isolation process in cell culture and improve phylogenetic and functional genome analysis. Moreover, the viral load in our patient was high enough for efficient transmission of MAYV to a susceptible mosquito vector (S. Becker, pers. comm.). Thus, in disease-endemic regions, patients with an acute MAYV infection should be protected from mosquito bites during the first week of disease to prevent spread of the virus.
This letter is dedicated to the late Ursula Herrmann (1927–2014), for making this study possible.
- Azevedo RS, Silva EV, Carvalho VL, Rodrigues SG, Nunes-Neto JP, Monteiro H, Mayaro fever virus, Brazilian Amazon. Emerg Infect Dis. 2009;15:1830–2 .
- Halsey ES, Siles C, Guevara C, Vilcarromero S, Jhonston EJ, Ramal C, Mayaro virus infection, Amazon Basin region, Peru, 2010–2013. Emerg Infect Dis. 2013;19:1839–42 .
- Taylor SF, Patel PR, Herold TJ. Recurrent arthralgias in a patient with previous Mayaro fever infection. South Med J. 2005;98:484–5 .
- Hassing RJ, Leparc-Goffart I, Blank SN, Thevarayan S, Tolou H, van Doornum G, Imported Mayaro virus infection in the Netherlands. J Infect. 2010;61:343–5. Epub 2010 Jun 19.
- Receveur MC, Grandadam M, Pistone T, Malvy D. Infection with Mayaro virus in a French traveller returning from the Amazon region, Brazil, January, 2010. Euro Surveill. 2010;15:19563 .
- Neumayr A, Gabriel M, Fritz J, Günther S, Hatz C, Schmidt-Chanasit J, Mayaro virus infection in traveler returning from Amazon Basin, northern Peru. Emerg Infect Dis. 2012;18:695–6.
- Theilacker C, Held J, Allering L, Emmerich P, Schmidt-Chanasit J, Kern WV, Prolonged polyarthralgia in a German traveller with Mayaro virus infection without inflammatory correlates. BMC Infect Dis. 2013;13:369.
- Eshoo MW, Whitehouse CA, Zoll ST, Massire C, Pennella TT, Blyn LB, Direct broad-range detection of alphaviruses in mosquito extracts. Virology. 2007;368:286–95.
- Powers AM, Aguilar PV, Chandler LJ, Brault AC, Meakins TA, Watts D, Genetic relationships among Mayaro and Una viruses suggest distinct patterns of transmission. Am J Trop Med Hyg. 2006;75:461–9 .
- Forshey BM, Guevara C, Laguna-Torres VA, Cespedes M, Vargas J, Gianella A, Arboviral etiologies of acute febrile illnesses in Western South America, 2000–2007. PLoS Negl Trop Dis. 2010;4:e787.
Suggested citation for this article: Friedrich-Jänicke B, Emmerich P, Tappe D, Günther S, Cadar D, Schmidt-Chanasit J. Genome analysis of Mayaro virus imported to Germany from French Guiana [letter]. Emerg Infect Dis [Internet]. 2016 Jul [date cited]. http://dx.doi.org/10.3201/eid2007.140043
1These authors contributed equally to this article.
Comments to the Authors
Comments to the EID Editors
Please contact the EID Editors via our Contact Form.
- Page created: June 18, 2014
- Page last updated: June 18, 2014
- Page last reviewed: June 18, 2014
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)